Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The group was the lead on manufacturing scale-up of the University of Oxford COVID-19 vaccine up to the point of transfer to AstraZeneca. This included the development of the novel low-cost large-scale manufacturing process, and initiating the formation of the UK & international 'distributed manufacturing site' consortium which has produced over a billion doses.

It is also the lead on the University's Bioprocess and Analytical Development (BiPAD) team, with particular interest in bringing together clinical and bioprocess understanding to make small-scale GMP manufacturing more cost-effective, lowering the barrier to experimental medicine and early-phase clinical development of novel interventions. 

Professor Sandy Douglas is Co-Investigator on the EPSRC funded Future Vaccine Manufacturing Research Hub (Vax-Hub).